Turn Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.09next fiscal year
Monitoring Framework
Key Performance Indicators
EASI-50 Responder Rate at Week 4 (GX-03 vs. Vehicle) Quarterly9,260.0%Target: Statistically significant separation in Phase 3
Cash and Cash Equivalents Quarterly11.2MTarget: Sufficient to fund operations through Phase 2 readout and Phase 3 prep
Watch Items
- GX-03 Phase 2 Topline Data Readout in Moderate-to-Severe Atopic DermatitisTrigger: Mid-2026Action: Evaluate full efficacy profile (EASI-75, EASI-90) and safety data to finalize Phase 3 trial design.
- FDA End-of-Phase 2 Meeting and Regulatory Pathway AlignmentTrigger: Post-Phase 2 Topline ReadoutAction: Initiate formal FDA interactions to align on Phase 3 endpoints and adaptive trial design.
- Medline Partnership Commercial Launch and Revenue GenerationTrigger: Late 2026Action: Monitor initial product shipments and royalty/licensing revenue from advanced wound care products.
Research as of 19 Jun 2026